Cellectar BioSciences, Inc. Aktie News

Standortaktivierung für zulassungsrelevante Phase-3-Bestätigungsstudie mit Iopofosine I 131 eingeleitet; Einreichung der New Drug Application für Mitte 2027 im Rahmen des beschleunigten Zulassungsprogramms der FDA geplant

Günstiges Sicherheitsprofil und vorläufige klinische Aktivität bei rückfälligem/refraktärem multiplem Myelom nachgewiesen

Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in  Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy

Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM)

FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2026, and provide a corporate update on May 14, 2026, at 8:30 a.m. Easte...

83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response of 17.8 months FDA-requested dataset with ≥12-month follow-up on all patients strengthens regulatory positioning for accelerated approval and supports initiation of confirmatory trial in 4Q26 Compelling efficacy observed in post-BTKi patients, including ~64% MRR and durable responses exceeding 18 ...

Oversubscribed Financing Led by Nantahala Capital with Participation from Balyasny Asset Management, Caligan Partners, Janus Henderson Investors, SilverArc Capital Management, Stonepine Capital Management, Empery Asset Management LP, StemPoint Capital LP and other Dedicated Healthcare Funds along with Members of the Executive Management Team Financing of up to $140 Million Supports Confirmatory...